Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both

PaperCitations, authors & open-access status

Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 88 citations, 2016 year and bronze oa status.

88
Citations
2016
Year
bronze
OA Status

Related on ScholarIQ

Lazaros Andronis
Author
JAMA Oncology
Journal
Prostate Cancer Treatment and Research
Topic
Prostate Cancer Treatment and Research
Topic
Bone health and treatments
Topic
Prostate Cancer Diagnosis and Treatment
Topic
470M+ articles · free account